These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29285361)

  • 1. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
    Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
    Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
    Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
    Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.
    Watanabe K; Sugiyama T; Otsuka A; Miyake H
    Int Cancer Conf J; 2020 Jan; 9(1):32-35. PubMed ID: 31950015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.
    Danno T; Iwata S; Niimi F; Honda S; Okada H; Azuma T
    Case Rep Urol; 2021; 2021():9936330. PubMed ID: 34306793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma.
    Sato T; Maeta T; Abe R; Yamada H; Ishida K; Yashima-Abo A; Kiyohara K; Miyajima S; Ito S
    Case Rep Oncol; 2021; 14(1):343-346. PubMed ID: 33776727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 detection using
    Vento J; Mulgaonkar A; Woolford L; Nham K; Christie A; Bagrodia A; de Leon AD; Hannan R; Bowman I; McKay RM; Kapur P; Hao G; Sun X; Brugarolas J
    J Immunother Cancer; 2019 Jun; 7(1):144. PubMed ID: 31155004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
    Sodji Q; Klein K; Sravan K; Parikh J
    J Immunother Cancer; 2017 Aug; 5(1):62. PubMed ID: 28807004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
    Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
    Front Oncol; 2019; 9():1033. PubMed ID: 31649889
    [No Abstract]   [Full Text] [Related]  

  • 13. Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report.
    Ikarashi D; Nakamura Y; Shimodate H; Usui Y; Ujiie T; Obara W
    Urol Case Rep; 2019 May; 24():100839. PubMed ID: 31211050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report.
    Azuma T; Sugihara T; Honda S; Yoshizaki U; Niimi F; Tsuru I; Kume H
    Oncol Lett; 2019 Apr; 17(4):4011-4015. PubMed ID: 30881514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable response to nivolumab rechallenge in a patient with metastatic clear cell renal cell carcinoma.
    Fujiwara M; Shimada W; Yokoyama M; Koyanagi A; Shintaku H; Fukuda S; Waseda Y; Tanaka H; Yoshida S; Fujii Y
    IJU Case Rep; 2024 Jul; 7(4):293-296. PubMed ID: 38966764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [METASTATIC Mucinous Tubular and Spindle Cell Carcinoma Treated with Nivolumab Successfully : A Case Report].
    Takahashi Y; Numakura K; Aoyama Y; Okada S; Saito T; Muto Y; Koizumi A; Nara T; Chiba S; Kanda S; Saito M; Narita S; Inoue T; Satoh S; Nanjo H; Habuchi T
    Hinyokika Kiyo; 2019 Sep; 65(9):363-367. PubMed ID: 31697878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report.
    Hori K; Hirohashi Y; Aoyagi T; Taniguchi N; Murakumo M; Miyata H; Torigoe T; Abe T; Shinohara N; Morita K
    Exp Ther Med; 2020 Mar; 19(3):1903-1907. PubMed ID: 32104247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
    Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
    Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.